<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04665206</url>
  </required_header>
  <id_info>
    <org_study_id>VT3989-001</org_study_id>
    <nct_id>NCT04665206</nct_id>
  </id_info>
  <brief_title>Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations</brief_title>
  <official_title>Phase 1, Multi-Center, Open-Label, Study to Evaluate the Safety, Tolerability, and PK of VT3989 in Patients With Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the NF2 Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vivace Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vivace Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, dose escalation and expansion study to evaluate the safety,&#xD;
      tolerability, PK, and biological activity of VT3989 administered once-daily in patients with&#xD;
      advanced pleural malignant mesothelioma and/or metastatic solid tumors that are resistant or&#xD;
      refractory to standard therapy or for which no effective standard therapy is available.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose escalation will employ a traditional 3 + 3 design to assess safety of VT3989 in patients&#xD;
      with refractory metastatic solid tumors or advanced malignant pleural mesothelioma until the&#xD;
      maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is determined. The RP2D may&#xD;
      be less than the MTD depending on the type and severity of AEs that occur during and after&#xD;
      the first cycle.&#xD;
&#xD;
      In Dose Expansion, patients will be enrolled into 2 cohorts: Cohort 1 - malignant pleural&#xD;
      mesothelioma patients with mutations of NF2 that have progressed on or following standard&#xD;
      therapy; and Cohort 2 - solid tumor patients with mutations of NF2 that have progressed on or&#xD;
      following standard therapy. Patients will be treated at the MTD or RP2D identified in Part 1,&#xD;
      to provide further characterization of the safety, tolerability, efficacy, and biological&#xD;
      activity of VT3989.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part 1 dose escalation: 3 + 3 design Part 2 dose expansion: 2 parallel cohorts</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Dose Limiting Toxicity</measure>
    <time_frame>over the first 21 days of dosing</time_frame>
    <description>Incidence of Adverse and Serious Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of General Toxicity</measure>
    <time_frame>through study completion, an average of 30 months</time_frame>
    <description>Incidence of Adverse and Serious Adverse Events, Discontinuations due to Adverse Events and general safety Evaluations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>through study completion, an average of 30 months</time_frame>
    <description>Determined by RECIST v1.1 or modified RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation - Cmax</measure>
    <time_frame>over first 21 days of dosing</time_frame>
    <description>Peak plasma concentration of VT3989</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation - Tmax</measure>
    <time_frame>over first 21 days of dosing</time_frame>
    <description>Time to reach peak plasma concentration of VT3989</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation - Half-life</measure>
    <time_frame>over first 21 days of dosing</time_frame>
    <description>Time required for the plasma concentration of VT3989 to reduce by half after reaching peak</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <condition>Mesothelioma</condition>
  <arm_group>
    <arm_group_label>VT3989 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VT3989 dosed orally in 21 day cycles. Patients will be enrolled into escalating dose levels during the Dose Escalation Phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VT3989 dosed in 21 day cycles in patients with refractory metastatic solid tumors, or advanced pleural malignant mesothelioma, with NF2 mutant tumors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VT3989</intervention_name>
    <description>25 or 100 mg capsules for oral administration.</description>
    <arm_group_label>Dose Expansion</arm_group_label>
    <arm_group_label>VT3989 Dose Escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Part 1: pathologically diagnosed metastatic solid tumor or advanced malignant pleural&#xD;
             mesothelioma that has progressed on or after standard of care therapy with evaluable&#xD;
             or measurable disease per RECIST v1.1&#xD;
&#xD;
          -  Part 2: pathologically diagnosed advanced malignant pleural mesothelioma with NF2&#xD;
             mutations (Cohort 1) or metastatic solid tumors with NF2 mutation (Cohort 2), for&#xD;
             which there is no further standard of care therapy available with measurable disease&#xD;
             per RECIST v1.1 for solid tumors or modified RECIST v1.1 for malignant pleural&#xD;
             mesothelioma&#xD;
&#xD;
          -  ECOG: 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active brain metastases&#xD;
&#xD;
          -  History of leptomeningeal metastases&#xD;
&#xD;
          -  Active or chronic, uncontrolled bacterial, viral, or fungal infection(s) requiring&#xD;
             systemic therapy&#xD;
&#xD;
          -  HIV positive or active Hepatitis B or Hepatitis C&#xD;
&#xD;
          -  Clinically significant cardiovascular disease&#xD;
&#xD;
          -  Additional active malignancy that may confound the assessment of the study endpoints&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Heather Fritz</last_name>
    <phone>650-627-7437</phone>
    <email>hfritz@inclin.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jill Abbey</last_name>
    <phone>925-286-0832</phone>
    <email>jabbey@vivacetherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCullum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 5, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

